555552
Rho Kinase Inhibitor
≥95% (HPLC), G-protein Rho-associated kinase inhibitor, liquid
Synonim(y):
InSolution Rho Kinase Inhibitor, Rho Kinase Inhibitor
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
| Gabaryty przesyłki | SKU | Dostępność | Cena netto |
|---|---|---|---|
| 500 μg | Sprawdź dostępność w koszyku | 652,00 zł |
Informacje o tej pozycji
Wzór liniowy:
C16H21N3O2S.2HCl
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥95% (HPLC)
Form:
liquid
Quality level:
Storage condition:
OK to freeze, protect from light
652,00 zł
Sprawdź dostępność w koszyku
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócNazwa produktu
Rho Kinase Inhibitor, InSolution, ≥95%
Quality Level
assay
≥95% (HPLC)
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
storage temp.
−20°C
General description
A cell-permeable isoquinolinesulfonamide compound that acts as a highly specific, potent, and ATP-competitive inhibitor of G-protein Rho-associated kinase (ROCK; Ki = 1.6 nM). Inhibits other serine/threonine kinases only at higher concentrations (Ki = 630 nM for PKA, 9.27 µM for PKC, and 10.1 µM for MLCK). Shown to selectively block lysophosphatidic acid-induced, but not PDBu-induced, phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in NT-2 cells (IC50 = 2.5 µM). Reported to be a more potent and selective inhibitor than Y-27632 (Cat. No. 688000 & 688001).
The InSolution Rho Kinase Inhibitor controls the biological activity of Rho Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Biochem/physiol Actions
Cell permeable: no
Primary Target
ROCK
ROCK
Product competes with ATP.
Target Ki: 1.6 nM against Rho-associated kinase (ROCK)
Physical form
A 10 mM (500 µg/128 µl) solution of Rho Kinase Inhibitor (Cat. No. 555550) in H₂O.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Other Notes
Ikenoya, M., et al. 2002. J. Neurochem.81, 9.
Sasaki, Y., et al. 2002. Pharmacol. Ther.93, 225.
Sasaki, Y., et al. 2002. Pharmacol. Ther.93, 225.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful (C)
Ta strona może zawierać tekst przetłumaczony maszynowo.
1 of 1
Ta pozycja | |||
|---|---|---|---|
| assay ≥95% (HPLC) | assay ≥95% (HPLC) | assay ≥98% (HPLC) | assay ≥95% (HPLC) |
| form liquid | form solid | form solid | form liquid |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| manufacturer/tradename Calbiochem® | manufacturer/tradename Calbiochem® | manufacturer/tradename Calbiochem® | manufacturer/tradename Calbiochem® |
| storage temp. −20°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. −20°C |
| storage condition OK to freeze, protect from light | storage condition OK to freeze, desiccated (hygroscopic), protect from light | storage condition OK to freeze, protect from light | storage condition OK to freeze, protect from light |
Klasa składowania
12 - Non Combustible Liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Powiązane treści
Harini Narasimhan et al.
Biology, 11(10) (2022-10-28)
TNBC represents the most aggressive breast cancer subtype. Although cancer stem cells (CSCs) are a minor fraction of all cancer cells, they are highly cancerous when compared to their non-stem counterparts, playing a major role in tumor recurrence and metastasis.
Xiao Li et al.
International journal of molecular sciences, 21(2) (2020-01-16)
Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen and progesterone receptors (ER, PR) and lacking an overexpression of human epidermal growth factor receptor 2 (HER2). Apart from this lack of therapeutic targets
Katrin Raute et al.
Cancer immunology research, 11(6), 810-829 (2023-05-04)
There are no targeted therapies for patients with triple-negative breast cancer (TNBC). TNBC is enriched in breast cancer stem cells (BCSC), which play a key role in metastasis, chemoresistance, relapse, and mortality. γδ T cells hold great potential in immunotherapy
Numer pozycji handlu globalnego
| SKU | NUMER GTIN |
|---|---|
| 555552-500UG | 04055977268423 |